Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

bioasis technologies

Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain….
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an…
Bioasis Technologies (BTI.V) hired Shadow Lake Group, and affiliate, SLG Europe BV, as a business development adviser earlier this week, according to a press release.   This one’s a…
Bioasis Technologies (BTI.V) announces today that the Japanese Patent Office (JPO) has issued Japanese Patent No.2019-189551 Notice of Allowance for the Company’s  xB3™-IDS fusion proteins. “We are excited about…
Bioasis Technologies (BTI.V) announced positive results today from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis (MS). “These…
Bioasis Technologies (BTI.V) announced they are entering into a research collaboration with Oxyrane UK. As Equity Guru previously reported, Bioasis is developing the xB³ platform, which aims penetrate the…
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according…